Vanguard Group Inc. Purchases 5,900,668 Shares of Tempus AI, Inc. $TEM

Key Points

• Vanguard Group Inc. significantly increased its stake in Tempus AI, purchasing an additional 5,900,668 shares, bringing its total ownership to approximately 3.48%, valued at about $289 million.
• Insider sales at Tempus AI include CEO Eric P. Lefkofsky selling 250,000 shares worth over $17 million, and EVP Erik Phelps selling over 51,000 shares, indicating a notable decrease in their holdings.
• Tempus AI reported a revenue of $314.64 million for the last quarter, exceeding estimates and marking an 89.5% increase compared to the previous year, despite a negative earnings per share of ($0.22).

Vanguard Group Inc. increased its position in shares of Tempus AI, Inc. (NASDAQ:TEM - Free Report) by 6,247.5% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 5,995,117 shares of the company's stock after acquiring an additional 5,900,668 shares during the period. Vanguard Group Inc. owned about 3.48% of Tempus AI worth $289,204,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also made changes to their positions in the company. IQ EQ FUND MANAGEMENT IRELAND Ltd boosted its position in shares of Tempus AI by 109.9% during the 1st quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 50,666 shares of the company's stock worth $2,444,000 after acquiring an additional 26,533 shares in the last quarter. Blair William & Co. IL boosted its position in shares of Tempus AI by 372.8% during the 1st quarter. Blair William & Co. IL now owns 32,334 shares of the company's stock worth $1,560,000 after acquiring an additional 25,495 shares in the last quarter. Manchester Capital Management LLC acquired a new stake in shares of Tempus AI during the 1st quarter worth approximately $63,000. PNC Financial Services Group Inc. boosted its position in shares of Tempus AI by 707.5% during the 1st quarter. PNC Financial Services Group Inc. now owns 4,716 shares of the company's stock worth $228,000 after acquiring an additional 4,132 shares in the last quarter. Finally, Liberty Mutual Group Asset Management Inc. acquired a new stake in shares of Tempus AI during the 1st quarter worth approximately $1,168,000. Institutional investors and hedge funds own 24.22% of the company's stock.

Analyst Upgrades and Downgrades

TEM has been the topic of several analyst reports. Guggenheim increased their price target on shares of Tempus AI from $65.00 to $75.00 and gave the stock a "buy" rating in a research report on Monday, June 30th. BTIG Research raised their target price on shares of Tempus AI from $75.00 to $85.00 and gave the company a "buy" rating in a research report on Wednesday. Bank of America raised their target price on shares of Tempus AI from $68.00 to $70.00 and gave the company a "neutral" rating in a research report on Wednesday, June 25th. Piper Sandler restated a "neutral" rating on shares of Tempus AI in a research report on Friday, August 8th. Finally, Morgan Stanley raised their target price on shares of Tempus AI from $65.00 to $68.00 and gave the company an "overweight" rating in a research report on Tuesday, August 12th. Six investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat, Tempus AI currently has a consensus rating of "Moderate Buy" and an average target price of $67.64.

Insider Activity

In other news, EVP Erik Phelps sold 51,317 shares of the firm's stock in a transaction on Monday, June 16th. The shares were sold at an average price of $72.56, for a total transaction of $3,723,561.52. Following the completion of the transaction, the executive vice president owned 97,779 shares of the company's stock, valued at approximately $7,094,844.24. This trade represents a 34.42% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Ryan Fukushima sold 17,460 shares of the firm's stock in a transaction on Tuesday, August 19th. The shares were sold at an average price of $74.65, for a total transaction of $1,303,389.00. Following the transaction, the chief operating officer directly owned 839,180 shares of the company's stock, valued at $62,644,787. The trade was a 2.04% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 776,451 shares of company stock valued at $53,022,688. 27.60% of the stock is currently owned by company insiders.

Tempus AI Trading Up 4.7%

Shares of TEM stock traded up $3.43 during trading hours on Thursday, hitting $76.71. 15,592,527 shares of the company's stock traded hands, compared to its average volume of 11,130,016. The stock's 50 day simple moving average is $63.59 and its 200 day simple moving average is $59.09. The stock has a market cap of $13.33 billion, a PE ratio of -64.46 and a beta of 4.98. Tempus AI, Inc. has a 12 month low of $31.36 and a 12 month high of $91.45. The company has a quick ratio of 1.43, a current ratio of 1.54 and a debt-to-equity ratio of 2.58.

Tempus AI (NASDAQ:TEM - Get Free Report) last released its quarterly earnings results on Friday, August 8th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.01. The firm had revenue of $314.64 million during the quarter, compared to the consensus estimate of $296.84 million. Tempus AI had a negative net margin of 20.98% and a negative return on equity of 122.86%. The company's revenue for the quarter was up 89.5% on a year-over-year basis. During the same quarter last year, the firm earned ($6.86) earnings per share. Tempus AI has set its FY 2025 guidance at EPS. On average, sell-side analysts anticipate that Tempus AI, Inc. will post -6.15 EPS for the current year.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.